HK1056117A1 - Treatment of hepatitis C with thymosin and pegylated interferon - Google Patents

Treatment of hepatitis C with thymosin and pegylated interferon

Info

Publication number
HK1056117A1
HK1056117A1 HK03108409A HK03108409A HK1056117A1 HK 1056117 A1 HK1056117 A1 HK 1056117A1 HK 03108409 A HK03108409 A HK 03108409A HK 03108409 A HK03108409 A HK 03108409A HK 1056117 A1 HK1056117 A1 HK 1056117A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
thymosin
pegylated interferon
treatment
effective amount
Prior art date
Application number
HK03108409A
Other languages
English (en)
Inventor
Alfred Rudolph
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of HK1056117A1 publication Critical patent/HK1056117A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK03108409A 2000-08-07 2003-11-19 Treatment of hepatitis C with thymosin and pegylated interferon HK1056117A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22331200P 2000-08-07 2000-08-07
PCT/US2001/041549 WO2002011754A1 (en) 2000-08-07 2001-08-06 Treatment of hepatitis c with thymosin and pegylated interferon

Publications (1)

Publication Number Publication Date
HK1056117A1 true HK1056117A1 (en) 2004-02-06

Family

ID=22835968

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03108409A HK1056117A1 (en) 2000-08-07 2003-11-19 Treatment of hepatitis C with thymosin and pegylated interferon

Country Status (12)

Country Link
EP (1) EP1311286B1 (da)
CN (1) CN1461221A (da)
AT (1) ATE332704T1 (da)
AU (2) AU8716001A (da)
CA (1) CA2418154A1 (da)
CY (1) CY1105657T1 (da)
DE (1) DE60121449T2 (da)
DK (1) DK1311286T3 (da)
ES (1) ES2267810T3 (da)
HK (1) HK1056117A1 (da)
PT (1) PT1311286E (da)
WO (1) WO2002011754A1 (da)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072961C (zh) * 1993-03-05 2001-10-17 施塞克龙药品公司 治疗对干扰素治疗无反应者的丙型肝炎的方法
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy

Also Published As

Publication number Publication date
ATE332704T1 (de) 2006-08-15
WO2002011754A1 (en) 2002-02-14
DE60121449D1 (de) 2006-08-24
CY1105657T1 (el) 2010-12-22
EP1311286B1 (en) 2006-07-12
CN1461221A (zh) 2003-12-10
EP1311286A1 (en) 2003-05-21
PT1311286E (pt) 2006-11-30
AU8716001A (en) 2002-02-18
AU2001287160B2 (en) 2005-08-18
ES2267810T3 (es) 2007-03-16
CA2418154A1 (en) 2002-02-14
DK1311286T3 (da) 2006-10-30
DE60121449T2 (de) 2007-02-01
EP1311286A4 (en) 2004-01-28

Similar Documents

Publication Publication Date Title
WO2000037110A3 (en) Ribavirin-pegylated interferon alfa induction hcv combination therapy
YU77000A (sh) Primena peg-ifn-alfa i ribavirina za lečenje hroničnog hepatitisa c
IL134345A0 (en) Methods for treatment of patients afflicted with multiple sclerosis using consensus interferon
IL161889A0 (en) Method for treating diseases with omega interferon
MD990258A (en) Method of treatment of the acute viral hepatitis B
HK1041215A1 (en) Use of thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir in manufacturing pharmaceutical combination preparations for treating hepatitis b infection.
MD2549G2 (ro) Metodă de tratament a hepatitei virale cronice C.
IL154299A0 (en) Treatment of hepatitis c with thymosin, interferon and ribavirin
AU8716001A (en) Treatment of hepatitis c with thymosin and pegylated interferon
IL159770A0 (en) Calcium salts with cytotoxic activity
FI954127A (fi) Menetelmä C-hepatiitin hoitamiseksi interferonihoitoon reagoimattomissa potilaissa
WO2001045642A3 (en) Pulmonary delivery of ribavirin or levovirin™ for systemic and quasi-systemic treatment of disease
James Ribavirin approved for hepatitis C combination treatment
MXPA05007901A (es) Terapia de combinacion para hcv.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
WO2003059334A3 (en) Gemcitabine in the treatment of smallpox
MXPA05008425A (es) Metodo de tratamiento con nelfinavir.
WO2002076405A3 (en) Compositions and methods of treatment of ulcerating diseases, burns, and related conditions
RU96122776A (ru) Способ лечения токсических форм дифтерии
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120806